Policy & Regulation
Sanofi and Regeneron's Dupixent meets all endpoints in pivotal AFRS study; sBLA accepted for FDA priority review
7 November 2025 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) on Friday announced positive results from the phase 3 LIBERTY-AFRS-AIMS study evaluating Dupixent (dupilumab) ...
MavriX Bio reports first patient dosed in Phase 1/2 trial of MVX-220 for AS
7 November 2025 - Clinical-stage biotechnology company MavriX Bio and AS2Bio, a drug development accelerator established by the Foundation for Angelman Syndrome Therapeutics (FAST), announced on Thurs...
Johnson & Johnson's DARZALEX FASPRO receives US FDA approval
7 November 2025 - Healthcare products company Johnson & Johnson (J&J) (NYSE:JNJ) announced on Thursday that it has received approval from the US Food and Drug Administration (FDA) for DARZALEX...
Calico Life Sciences' ABBV-CLS-628S granted US FDA Orphan Drug Designation
6 November 2025 - Calico Life Sciences LLC, a biotechnology company focused on ageing and age-related diseases, founded by Alphabet Inc (NASDAQ:GOOG) and Arthur D. Levinson, announced on Wednesday tha...
Lunai Bioworks publishes breakthrough on second-generation allogeneic dendritic cell therapy in vaccines
5 November 2025 - Lunai Bioworks (NASDAQ: LNAI), an AI-powered drug discovery and biodefence company, on Wednesday announced the publication of a landmark study detailing its second-generation allogen...
Oxford Nanopore and bioMérieux introduce AmPORE-TB for rapid tuberculosis resistance characterisation
5 November 2025 - French diagnostics company bioMérieux (Euronext Paris:BIM) and UK-based molecular sensing technology company Oxford Nanopore Technologies (LON:ONT) on Wednesday announced the ...